实体瘤免疫细胞治疗研究前沿与挑战  

Frontiers and challenges of immune cell therapy research in solid tumors

作　　者：邢晓芳 王子凡[2] 吴名 姚刚 Xiaofang Xing;Zifan Wang;Ming Wu;Gang Yao(Department of Health Sciences,National Natural Science Foundation of China,Beijing 100085,China;Department of Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Mengchao Hepatobiliary Hospital of Fujian Medical University,Fuzhou 350025,China)

机构地区：[1]国家自然科学基金委员会医学科学部,北京100085 [2]北京大学肿瘤医院,北京市肿瘤防治研究所,北京100142 [3]福建医科大学孟超肝胆医院,福州350025

出　　处：《科学通报》2024年第26期3952-3969,共18页Chinese Science Bulletin

摘　　要：嵌合抗原受体T细胞(chimeric antigen receptor T,CAR-T)治疗在血液系统肿瘤中显示出的良好效果,带动了整个免疫细胞疗法的发展,以T细胞为主的免疫细胞治疗也逐渐迈入实体瘤时代,但目前仍然面临很多严峻的挑战.肿瘤异质性、浸润受阻和抑制性免疫微环境仍是目前免疫细胞治疗实体瘤的主要障碍.随着合成生物学、基因工程技术、高通量测序及生物材料等前沿科学技术的发展,免疫细胞治疗技术手段也在不断进步,针对实体瘤免疫细胞治疗的技术瓶颈,目前研究的重点主要集中在如何提高疗效、增加安全性、拓宽细胞来源等方面,旨在开发更加安全有效的治疗策略.本文综述实体瘤免疫细胞治疗领域基础研究的前沿现状、面临的挑战和未来的发展,以期为本领域的研究提供参考.Tumor immune cell therapy employs activated and modulated patient or donor immune cells to recognize and kill tumor cells,thereby inhibiting tumor growth and spread.Currently,the main forms of immune cell therapy include chimeric antigen receptor T-cell(CAR-T),T-cell receptor-engineered T-cell(TCR-T),tumor-infiltrating lymphocyte(TIL),and natural killer(NK)cell therapies.The success of CAR-T therapy in hematological malignancies has accelerated the development of T-cell-based immune cell therapies for solid tumors.Recently,Lifileucel was granted accelerated approval by the FDA for patients with melanoma,marking the first approved TIL therapy and the first T-cell therapy approved for solid tumors.Moreover,CAR-T therapy targeting CLDN18.2 has exhibited promising efficacy in gastrointestinal tumors,and GD2-targeting CAR-T therapy has obtained encouraging results in gliomas,while TCR-T therapy targeting tumorassociated antigens(including NY-ESO and MAGE-A3)has demonstrated significant antitumor activity in diseases such as synovial sarcoma and uveal melanoma.However,the effective response rate and beneficiary population of immune cell therapy remain limited in most solid tumors,owning to tumor antigen heterogeneity,infiltration obstacles,suppressive immune microenvironments,and limited cell source availability.With advancements in scientific and technological approaches such as synthetic biology,genetic engineering,high-throughput sequencing,and the development of biomaterials,next-generation immune cell technologies are rapidly evolving to enhance efficacy,safety,and cell source expansion.Overexpression of chemokine receptors and cytokines,knockout of immune inhibitory signaling molecules,and combination therapies such as chemotherapy,radiotherapy,and immune checkpoint blockade have made substantial progress in improving the immunosuppressive environment.Research on multi-target tandem,Boolean logic designs,and innate immune cells has shown the potential for enhancing safety.Universal cells,nonviral vectors,and in v

关 键 词：继承性细胞免疫疗法 肿瘤 嵌合抗原受体 T细胞受体 肿瘤浸润淋巴细胞 

分 类 号：R730.51[医药卫生—肿瘤]